Aim: Several studies investigated sequencing of aRCC therapies but none have evaluated real world outcomes in patients treated with first-line PAZ who then switched to mTORi therapy. Methods: A retrospective, longitudinal analysis and chart review using US Oncology's iKnowMed electronic health records database. Adults (≥18 years) with aRCC (Stage III/IV), at least 2 visits, received PAZ first-line therapy, had evidence of progressive disease and then received either everolimus (EVE) or temsirolimus (TEM) as second-line therapy from 1-Nov-2009 to 31-Aug-2012 were included. Exclusion criteria were diagnosis of other primary cancer, first-line therapy other than PAZ or enrollment in clinical trials. Key outcomes were overall survival (OS -months from mTORi initiation until death or censoring), progression-free survival (PFS -months from mTORi initiation until first progression, death or censoring), time to treatment failure (TTF -months from mTORi initiation until treatment failure or censoring), adverse events, and treatment patterns. Cases were followed to 31-Oct-2013.
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Results: Of 177 patients on first-line PAZ, 35 went onto second-line EVE (n = 24) or TEM (n = 11). Baseline characteristics and clinical outcomes are shown below. Adverse events >20% incidence included fatigue (51%) and nausea (34%). Average duration of treatment (SD) for EVE was 180 (191) days; the main reason for discontinuing therapy was toxicity (45%). For TEM, average duration (SD) was 56 (19) days; progression (43%) was the main reason for discontinuation. 
